CSPI Alleges Infant Formula Misbranding to FDA

On February 10, 2021, the Center for Science in the Public Interest (CSPI) sent a letter to the U.S. Food and Drug Administration urging it to take enforcement action against the marketing of various products labeled as infant formula but marketed for use by children over 12 months. In its letter, CSPI argues that the... Continue Reading